AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
52 patients (estimated)
Sponsors
Massachusetts General Hospital
Collaborators
AstraZeneca
Tags
Kinase Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1560
NCT Identifier
NCT03770429

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.